| Parameter | Specification |
|---|---|
| Mechanism | Hemodynamic systolic pressure ratio (Doppler-guided) [1][2] |
| Key Spec | Systolic pressure ratio (Normal: 1.00 - 1.40) [3] |
| Protocol | Doppler-guided bilateral arm and ankle pressure measurements [1:1][2:1] |
| Distance | N/A (Stationary/resting or treadmill-based) [1:2] |
| FDA Class | Class II Diagnostic Device |
| Entry Cost | $100 - $3,000 (clinic-grade Doppler setups) |
The Ankle-Brachial Index (ABI) is the gold-standard noninvasive physiological test used to screen for and diagnose lower-extremity peripheral artery disease (PAD) [1:3][4]. It serves as a highly validated, cost-effective tool to quantify the severity of arterial stenosis, guide clinical management, and stratify systemic cardiovascular risk in both symptomatic and high-risk asymptomatic populations [1:4][5]. In the context of value-based medicine, optimizing clinical outcomes for intermittent claudication focuses on reducing cardiovascular risk and improving functional performance, whereas advanced imaging modalities are cost-effective primarily when reserved for preprocedural planning [6].
The resting ABI is not merely a tool for detecting local leg blockages; it is a profound window into systemic cardiovascular health [2:2]. Because atherosclerosis is a systemic process, the presence of obstructive lesions in the lower limbs reflects a high probability of similar plaque burden in the coronary and cerebral circulations [9:1][2:3].
Identifying a low ABI is highly actionable. In individuals with subclinical or asymptomatic PAD, a low ABI reclassifies them into a higher cardiovascular risk tier [12], prompting aggressive lipid-lowering therapy (such as statins) [13], blood pressure control [14], and dual antithrombotic therapies where indicated [15]. Emerging observational data suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a significant reduction in both major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in patients with moderate PAD [16].
Under normal physiological conditions at rest, the systolic blood pressure in the lower extremities is equivalent to or slightly higher than that in the upper extremities [1:5][2:4]. In healthy individuals, the resulting ratio of ankle to brachial systolic pressure is at least 1.00 and typically does not exceed 1.40 [3:1].
When atherosclerosis develops within the lower-limb arterial tree—such as the aortoiliac, femoropopliteal, or infrapopliteal segments—luminal narrowing occurs [1:6][2:5]. This narrowing restricts distal blood flow to the lower limbs, reducing the systolic blood pressure in the distal ankle arteries (dorsalis pedis and posterior tibial) relative to the systemic systolic pressure measured in the brachial arteries [1:7][2:6].
Under resting conditions, lower-extremity blood flow may remain adequate even in the presence of mild-to-moderate arterial stenosis because the metabolic demands of the leg muscles at rest are relatively low [7:2][2:7]. As a result, resting distal ankle pressures may be maintained at normal or only borderline-reduced levels, potentially yielding a normal or "borderline" resting ABI (0.91–0.99) despite anatomical arterial narrowing [1:8][7:3][2:8].
However, physical exertion (such as walking) triggers a dramatic increase in the oxygen and metabolic demands of the lower extremity skeletal muscles, which normally prompts profound distal vasodilation and increased blood flow [1:9][2:9]. In the presence of a hemodynamically significant stenosis, the restricted arterial lumen prevents the necessary compensatory increase in blood volume flow [1:10][17]. Consequently, during or immediately after exercise, distal perfusion pressure drops precipitously, resulting in a significant drop in ankle systolic pressure and a decreased post-exercise ABI [1:11][17:1]. This hemodynamic failure under stress forms the clinical basis for exercise ABI testing to unmask obstructive disease that remains compensated at rest [1:12][17:2].
The execution of a standardized, diagnostic-grade ABI requires specific, calibrated clinical equipment [1:13]:
To calculate the ABI, separate indices are calculated for the right and left lower extremities. The mathematical equations are strictly standardized [1:18]:
Where:
The denominator for both limbs is always the higher of the two brachial pressures [1:19]. This systemic reference shields the calculation from false inflation if one subclavian artery has stenotic disease (which would lower the measured pressure in that specific arm) [1:20][2:12]. While the traditional ABI is calculated using the higher of the two ankle pressures, some research indicates that an alternative calculation method using the lower of the two ankle pressures can identify additional at-risk individuals with high mortality risk who are missed by standard calculations [19].
The clinical interpretation of the calculated resting ABI is highly standardized based on highly validated diagnostic and prognostic thresholds [20][3:2]:
| Calculated ABI Range | Clinical Classification | Guideline Context & Clinical Interpretation |
|---|---|---|
| >1.40 | High ABI | Indicates arterial stiffness or noncompressibility (often due to medial calcification). Associated with an elevated risk of MACE and mortality [3:3]. |
| 1.00 – 1.40 | Normal Perfusion | Normal arterial hemodynamics. Low probability of active lower-extremity obstructive arterial disease [20:1][3:4]. |
| 0.90 – 0.99 | Borderline | Equivocal range. Associated with increased cardiovascular risk and warrants further clinical evaluation if symptoms are present [3:5]. |
| <0.90 | Low ABI (PAD) | Confirms lower-extremity peripheral artery disease (stenosis). Associated with significantly higher risk of MACE and cardiovascular mortality [5:2][3:6]. |
To minimize intra-operator variability and ensure diagnostic accuracy, the clinical measurement of the resting ABI must follow a highly structured, step-by-step protocol [1:21][2:13]:
| Outcome / Goal | Effect* | Consistency** | Evidence quality | Studies*** | Notes (population, duration, dose) |
|---|---|---|---|---|---|
| Diagnosis of Obstructive PAD | High | High | 10+ Diagnostic studies | Resting ABI ≤0.90 confirms lower extremity arterial stenosis [1:30][4:3]. | |
| Cardiovascular Risk Stratification | High | High | 20+ Prospective cohorts | Low ABI (≤0.90) is independently associated with an increased risk of MACE and all-cause mortality across high-risk cohorts [5:3][10:1]. | |
| Unmasking Subclinical Ischemia | High | Moderate | 5+ Clinical studies | Post-exercise ABI decline (defined as a drop of >20% from resting baseline ABI) confirms PAD in symptomatic patients with normal resting ABI [17:3]. | |
| Ischemic Risk in Calcified Arteries | High | Moderate | 8+ Cohorts | Toe-Brachial Index (TBI) <0.60 detects hidden arterial disease and predicts cardiovascular events even when ABI is normal [20:2]. | |
| Management of Chronic Limb-Threatening Ischemia | High | Moderate | 5+ Studies | In patients with severe PAD and tissue loss (wound/ulcer), low ABI is a critical indicator of poor perfusion, guiding revascularization decisions to prevent amputation [1:31]. |
e="[dir][mag][impact]" where dir = u|d|e|q, mag = 0|1|2|3, impact = p|n|x.[^1]) in the "Notes" column for every single row.The clinical utility of routine ABI screening in asymptomatic adults is a subject of ongoing debate, presenting a clear contrast between evidence-based government task forces and professional cardiovascular societies [21]:
The resting ABI is a powerful surrogate marker of systemic subclinical atherosclerosis [5:4][10:2]:
Standard guidelines highlight the limitations of screening in low-risk individuals and the critical importance of standardized clinical protocols over automated methods:
The primary clinical limitation of the standard ABI occurs in populations prone to Medial Arterial Calcification (MAC), historically known as Mönckeberg's Sclerosis [1:39][2:26][26:1]:
To bypass the diagnostic limits of noncompressible ankle arteries, the Toe-Brachial Index (TBI) must be utilized [1:44][20:3]:
Exercise ABI testing is indicated for patients presenting with classic exertional leg symptoms (intermittent claudication) who have a normal or borderline resting ABI (0.91 to 1.40) [1:47][7:4].
Technicians and clinicians must remain vigilant against several procedural and physiological confounders that can distort the ABI [1:53][2:33]:
Acute limb ischemia (ALI) is a sudden, rapid decrease in lower limb perfusion that threatens viability and represents an absolute medical emergency [1:65][7:5]. Rapid clinical recognition of sudden-onset limb perfusion deficits is vital. Key clinical signs indicating acute arterial occlusion include the sudden onset of severe lower limb pain, extreme pallor, pulselessness on Doppler exam, paresthesia (numbness), paralysis (loss of motor function), and poikilothermia (coldness of the limb relative to the other) [1:66][7:6]. The emergence of these signs, particularly sensory or motor loss, indicates that the limb is in immediate jeopardy, and emergency transfer to a vascular surgery specialist is mandatory [1:67][7:7].
Using the higher of the two brachial pressures is a protective clinical standard designed to safeguard the calculation against subclavian artery stenosis [1:68][2:38]. If a patient has an asymptomatic narrowing of the left subclavian artery, the blood pressure in the left arm will be falsely low (e.g., 100 mmHg), while the right arm reflects the true systemic blood pressure (e.g., 130 mmHg). If the lower left brachial pressure were used as the denominator for the left leg, it would falsely inflate the calculated left ABI, potentially masking a real lower extremity perfusion deficit [1:69][2:39]. Using the higher of the two brachial pressures ensures that the denominator always represents the true, highest systemic perfusion pressure [1:70].
An ABI >1.40 indicates that the ankle arteries are noncompressible due to advanced medial arterial calcification [1:71][2:40][26:7]. This is highly common in patients with diabetes or chronic kidney disease [1:72][26:8]. Because the ABI is hemodynamically invalid in this scenario, clinicians must perform a Toe-Brachial Index (TBI) using specialized small toe cuffs and a photoplethysmography (PPG) or Doppler sensor [1:73][20:6]. Digital arteries in the toes are rarely affected by medial calcification, allowing for accurate, compressible pressure readings. A TBI <0.60 is diagnostic of PAD [20:7].
The resting ABI test is performed after quiet, supine rest to assess baseline perfusion under resting hemodynamic conditions [1:74]. However, resting pressures can remain normal in patients with moderate PAD due to collateral vessel compensation [1:75][2:41]. The exercise ABI test involves walking on a treadmill or performing active heel raises to increase lower extremity skeletal muscle metabolic demand [1:76][2:42]. Under this exertional stress, distal vasodilation occurs, and if a hemodynamically significant stenosis is present, the distal pressure drops sharply. A post-exercise ABI drop of >20%, or an ankle SBP drop of >30 mmHg, is diagnostic of PAD, even if the resting ABI was completely normal [1:77][17:6].
Yes. An ABI of 0.95 falls within the "borderline" range (0.91 to 0.99), which can easily occur in patients with anatomical arterial stenosis who have developed highly efficient collateral circulation at rest, or who have mild medial calcification that slightly inflates their ankle pressure [1:78][2:43][26:9]. If such a patient has exertional leg symptoms, a resting ABI of 0.95 cannot exclude PAD. These individuals must undergo an Exercise ABI test or a Toe-Brachial Index (TBI) to evaluate lower limb perfusion under metabolic stress or bypass ankle vessel stiffness [1:79][20:8][17:7].
Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease. Journal of the American College of Cardiology. 2024;83(24):e1110-e1247. https://pubmed.ncbi.nlm.nih.gov/38752899/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kim ES, Wattanakit K, Gornik HL. Using the ankle-brachial index to diagnose peripheral artery disease and assess cardiovascular risk. Cleveland Clinic Journal of Medicine. 2012;79(9):651-661. https://pubmed.ncbi.nlm.nih.gov/22949346/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Hiramori S, Soga Y, Kamioka N, et al. Clinical Impact of the Ankle-Brachial Index in Patients Undergoing Successful Percutaneous Coronary Intervention. Circulation Journal. 2018;82(6):1687-1694. https://pubmed.ncbi.nlm.nih.gov/29618695/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Guirguis-Blake JM, Evans CV, Redmond N, et al. Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;320(2):184-196. https://pubmed.ncbi.nlm.nih.gov/29998343/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Cardoso CRL, Melo JV, Salles GC, et al. Prognostic impact of the ankle-brachial index on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetologia. 2018;61(11):2300-2311. https://pubmed.ncbi.nlm.nih.gov/30112690/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Raskin D, Partovi S, Mills JL. A contemporary paradigm for value-based medicine in peripheral artery disease. Journal of Vascular Surgery. 2025;82(6):1812-1823. https://pubmed.ncbi.nlm.nih.gov/40784592/ ↩︎
Firnhaber JM, Powell CS. Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment. American Family Physician. 2019;99(6):362-369. https://pubmed.ncbi.nlm.nih.gov/30874413/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Herman WH, Kuo S. Is Screening for Heart Failure and Peripheral Artery Disease Warranted in Asymptomatic Adults With Diabetes? A Perspective on the 2025 American Diabetes Association "Standards of Care in Diabetes". Diabetes Care. 2025;48(9):1481-1488. https://pubmed.ncbi.nlm.nih.gov/40504992/ ↩︎ ↩︎
US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(2):177-183. https://pubmed.ncbi.nlm.nih.gov/29998344/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Liu L, Sun H, Nie F, et al. Prognostic Value of Abnormal Ankle-Brachial Index in Patients With Coronary Artery Disease: A Meta-Analysis. Angiology. 2020;71(6):534-541. https://pubmed.ncbi.nlm.nih.gov/32166959/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Nishimura H, Miura T, Minamisawa M, et al. Ankle-brachial Index for the Prognosis of Cardiovascular Disease in Patients with Mild Renal Insufficiency. Internal Medicine. 2017;56(16):2101-2108. https://pubmed.ncbi.nlm.nih.gov/28781301/ ↩︎
Ferket BS, Spronk S, Colkesen EB, et al. Systematic review of guidelines on peripheral artery disease screening. The American Journal of Medicine. 2012;125(2):197-208. https://pubmed.ncbi.nlm.nih.gov/22079018/ ↩︎ ↩︎ ↩︎ ↩︎
Ramos R, García-Gil M, Comas-Cufí M, et al. Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index. Journal of the American College of Cardiology. 2016;67(6):630-640. https://pubmed.ncbi.nlm.nih.gov/26868687/ ↩︎
Abraham AT, Mojaddedi S, Loseke IH, et al. Hypertension in Patients With Peripheral Artery Disease: An Updated Literature Review. Cureus. 2024;16(6):e63110. https://pubmed.ncbi.nlm.nih.gov/39006738/ ↩︎
Ferretto L, Penzo M, Bozza R, et al. Efficacy of dual therapy with Aspirin and rivaroxaban in symptomatic peripheral artery disease: the DOLOMITI experience. International Angiology. 2025;44(6):482-490. https://pubmed.ncbi.nlm.nih.gov/41416751/ ↩︎
Go CC, Annie F, Drabish K, et al. Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease. Journal of Vascular Surgery. 2025;82(3):885-893. https://pubmed.ncbi.nlm.nih.gov/40484062/ ↩︎
Hammad TA, Strefling JA, Zellers PR, et al. The Effect of Post-Exercise Ankle-Brachial Index on Lower Extremity Revascularization. JACC: Cardiovascular Interventions. 2015;8(10):1338-1345. https://pubmed.ncbi.nlm.nih.gov/26292588/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Chesbro SB, Asongwed ET, Brown J. Reliability of Doppler and stethoscope methods of determining systolic blood pressures: considerations for calculating an ankle-brachial index. Journal of the National Medical Association. 2011;103(9-10):861-867. https://pubmed.ncbi.nlm.nih.gov/22364054/ ↩︎ ↩︎
Nead KT, Cooke JP, Olin JW, et al. Alternative ankle-brachial index method identifies additional at-risk individuals. Journal of the American College of Cardiology. 2013;62(6):553-560. https://pubmed.ncbi.nlm.nih.gov/23707317/ ↩︎
Han M, Kim YD, Lee I, et al. Low Toe-Brachial Index Is Associated With Stroke Outcome Despite Normal Ankle-Brachial Index. Frontiers in Neurology. 2021;12:782163. https://pubmed.ncbi.nlm.nih.gov/34987463/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Uyagu OD, Ofoegbu C, Ikhidero J. Quality assessment and comparative analysis on the recommendations of current guidelines on screening and diagnosis of peripheral arterial disease: a systematic review. BMJ Open. 2022;12(9):e059102. https://pubmed.ncbi.nlm.nih.gov/36104133/ ↩︎ ↩︎ ↩︎
Moyer VA, US Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine. 2013;159(5):342-348. https://pubmed.ncbi.nlm.nih.gov/24026320/ ↩︎
Tehan PE, Barwick AL, Sebastian M, et al. Diagnostic accuracy of the postexercise ankle-brachial index for detecting peripheral artery disease in suspected claudicants with and without diabetes. Vascular Medicine. 2018;23(2):116-125. https://pubmed.ncbi.nlm.nih.gov/29432708/ ↩︎
Han M, Heo J, Jung JW, et al. Association between Low Ankle-Brachial Index and Poor Outcomes in Patients with Embolic Stroke of Undetermined Source. Journal of Clinical Medicine. 2022;11(11):3056. https://pubmed.ncbi.nlm.nih.gov/35683461/ ↩︎
Berkovitch A, Iakobishvili Z, Fuchs S, et al. Peripheral artery disease, abnormal ankle-brachial index, and prognosis in patients with acute coronary syndrome. Frontiers in Cardiovascular Medicine. 2022;9:956554. https://pubmed.ncbi.nlm.nih.gov/36148064/ ↩︎
Otsuka K, Nakanishi K, Shimada K, et al. Ankle-brachial index, arterial stiffness, and biomarkers in the prediction of mortality and outcomes in patients with end-stage kidney disease. Clinical Cardiology. 2019;42(7):695-702. https://pubmed.ncbi.nlm.nih.gov/31020665/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ueki Y, Miura T, Minamisawa M, et al. The usefulness of brachial-ankle pulse wave velocity in predicting long-term cardiovascular events in younger patients. Heart and Vessels. 2017;32(6):695-703. https://pubmed.ncbi.nlm.nih.gov/27822742/ ↩︎
Hammad TA, Hiatt WR, Gornik HL, et al. Prognostic value of an increase in post-exercise ankle-brachial index. Vascular Medicine. 2017;22(3):197-204. https://pubmed.ncbi.nlm.nih.gov/27940923/ ↩︎
Minc SD, McGinigle KL. Peripheral Artery Disease: New Concepts, Treatments, and Disparities. Annual Review of Medicine. 2026;77:331-344. https://pubmed.ncbi.nlm.nih.gov/41380712/ ↩︎